Methylfenidaat Hcl Sandoz Retard (Methylphenidate Hydrochloride)

Methylphenidate hydrochloride is a central nervous system stimulant used in disorders that affect attention and wakefulness.

• Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves attention, reduces hyperactivity and impulsivity, supporting better academic performance.
• Attention deficit hyperactivity disorder (ADHD) in adults: enhances focus and reduces distractibility, aiding occupational functioning.
• Narcolepsy: decreases excessive daytime sleepiness and improves overall alertness.

• Methylphenidate hydrochloride blocks the reuptake of dopamine and norepinephrine at neuronal synapses, increasing their extracellular concentrations in the central nervous system. The elevated catecholamine levels enhance neurotransmission in brain regions that regulate attention, impulse control and wakefulness, thereby producing its therapeutic effects in ADHD and narcolepsy. These actions modulate activity in the prefrontal cortex and basal ganglia, key areas involved in executive function and arousal.

Methylphenidate hydrochloride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Insomnia: difficulty falling or staying asleep, which may affect daytime functioning.
• Decreased appetite: reduced food intake that can lead to weight loss, especially in children.
• Headache: mild to moderate cranial pain that may be intermittent.
• Stomach pain: abdominal discomfort, nausea, or dyspepsia.

Serious or Rare Side Effects

• Cardiovascular events: increased heart rate, elevated blood pressure, or rare arrhythmias that require monitoring.
• Psychosis or severe mood changes: emergence of hallucinations, delusions, or manic‑like symptoms.
• Allergic reactions: rash, facial swelling, or anaphylaxis requiring immediate medical attention.

When prescribing methylphenidate hydrochloride, several precautions should be observed to ensure safe use.

• Cardiovascular assessment: evaluate heart rate, blood pressure, and cardiac history before initiating therapy.
• Psychiatric monitoring: watch for emergence or worsening of anxiety, depression, or psychotic symptoms.
• Growth monitoring: regularly assess height and weight in pediatric patients.
• Drug abuse potential: consider risk of dependence and misuse, especially in individuals with a history of substance abuse.
• Concomitant MAO inhibitors: avoid use within 14 days of MAO‑inhibitor therapy to prevent hypertensive crisis.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Methylphenidate hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may cause hypertensive crisis.
• Sympathomimetic agents: combined effect can lead to excessive cardiovascular stimulation.
• Antidepressants (e.g., tricyclics, SSRIs): may increase risk of serotonin syndrome or cardiac effects.

Moderate Interactions (Monitor Closely)

• Antihypertensives: methylphenidate may reduce their effectiveness, requiring dose adjustment.
• Anticonvulsants (e.g., carbamazepine): may decrease methylphenidate plasma levels.
• Acid‑reducing agents: may affect absorption, necessitating monitoring of therapeutic response.